It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2015
  5. Novel Anti-epileptic Drug E Keppra® Approved in Japan for Additional Indication as Monotherapy for Partial-onset Seizures, in Addition to Existing Indication as Adjunctive Therapy for These Seizures

February 20, 2015

Otsuka Pharmaceutical Co., Ltd.
UCB Japan Co. Ltd.

Pharmaceuticals

Novel Anti-epileptic Drug E Keppra® Approved in Japan for Additional Indication as Monotherapy for Partial-onset Seizures, in Addition to Existing Indication as Adjunctive Therapy for These Seizures

Otsuka Pharmaceutical Co., Ltd. and UCB Japan Co. Ltd. have been engaged in co-development and co-marketing of E Keppra® Tablets 250mg and 500mg, E Keppra® Dry Syrup 50%, and E Keppra® for IV Infusion 500mg (generic name: levetiracetam) in adjunctive therapy for partial-onset seizures. UCB Japan filed an application for a partial amendment of approval to use levetiracetam in monotherapy. The partial amendment has been approved for monotherapy for partial-onset seizures (including secondary generalized seizures) in patients with epilepsy as an additional indication.

  1. 1Calculated based on JPM(2013.1~12), ©2014 IMS Health, reprinted with permission, all rights reserved
  2. 2Overseas Guidelines including the International League Against Epilepsy (ILAE), Epilepsia 54 (3) 551-563; 2013, and UK NICE 2012
  3. 3Newer anti-epileptic drugs launched in Japan since 2006, including E Keppra

Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases